1. Home
  2. NLY vs BBIO Comparison

NLY vs BBIO Comparison

Compare NLY & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Annaly Capital Management Inc.

NLY

Annaly Capital Management Inc.

HOLD

Current Price

$21.21

Market Cap

15.2B

Sector

Real Estate

ML Signal

HOLD

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

HOLD

Current Price

$71.71

Market Cap

15.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NLY
BBIO
Founded
1996
2015
Country
United States
United States
Employees
212
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.2B
15.3B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
NLY
BBIO
Price
$21.21
$71.71
Analyst Decision
Buy
Strong Buy
Analyst Count
11
24
Target Price
$23.45
$85.43
AVG Volume (30 Days)
7.7M
1.6M
Earning Date
04-21-2026
04-28-2026
Dividend Yield
13.19%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$502,076,000.00
Revenue This Year
$188.83
$88.16
Revenue Next Year
$2.40
$74.13
P/E Ratio
$7.88
N/A
Revenue Growth
N/A
126.26
52 Week Low
$16.60
$30.08
52 Week High
$24.52
$84.94

Technical Indicators

Market Signals
Indicator
NLY
BBIO
Relative Strength Index (RSI) 41.72 52.60
Support Level $20.43 $70.65
Resistance Level $23.27 $78.20
Average True Range (ATR) 0.49 2.64
MACD 0.04 0.38
Stochastic Oscillator 38.02 55.27

Price Performance

Historical Comparison
NLY
BBIO

About NLY Annaly Capital Management Inc.

Annaly Capital Management Inc is an American mortgage real estate investment trust. Its business objective is to generate net income for distribution to its stockholders and optimize its returns through prudent management of its diversified investment strategies. The company's reportable operating segments are: the Agency segment, which invests in Agency mortgage-backed securities collateralized by residential mortgages; the Residential Credit segment, which invests in non-Agency residential whole loans and securitized products within the residential and commercial markets; the Mortgage Servicing Rights segment; and Corporate & Other. Maximum revenue for the company is generated from its Agency segment.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: